Roche has today announced new plans to spend 3 billion Swiss francs on upgrading and constructing new labs in Basel, Switzerland. Roche have put the plans forward to invest in creating modern, sustainable workplaces for their employees based in their site in Basel, Switzerland, creating new state-of-the-art offices. The plans include the construction of a
Mid-stage clinical data for Roche’s asthma drug, lebrikizumab, has demonstrated that the drug significantly reduced attacks in patients with severe uncontrolled asthma. Roche presented the Phase IIb clinical data at the American Academy of Allergy, Asthma and Immunology meeting in San Diego yesterday. The data from the clinical trials showed that asthma attacks were reduced
Scottish regulatory body, the Scottish Medicines Consortium (SMC), have approved Roche’s MabThera (rituximab) for the National Health Service (NHS) in Scotland. MabThera has been approved to treat two potentially life-threatening illnesses, GPA and MPA.
Roche have posted positive clinical trial Phase II results for lampalizumab when treating age-related macular degeneration (AMD). The clinical trial demonstrated that patients with the dry form of AMD had a 20% reduction in geographic atrophy after 18 months’ treatment.
Draft guidance issued today by the regulatory body, NICE (National Institute for Health and Care Excellence), has confirmed that the NHS in England and Wales has been advised not to routinely provide Roche’s Perjeta (pertuzumab). Perjeta was submitted as a treatment for a type of advanced breast cancer, but has been found not to represent value
The National Institute for Health and Clinical Excellence (NICE) has issued a second draft guidance to Roche asking them to provide additional information on the use of their skin cancer drug, Zelboraf (vemurafenib). The request concerns Zelboraf’s use in the treatment of unresectable locally-advanced or metatastic BRAF V600 mutation-positive melanoma, for which NICE announced, in
Illumina’s board of directors unanimously rejected Roche’s revived takeover bid yesterday, describing it as “opportunistic”. Last week, the Swiss major improved their offer by 15% to $51.00 per share, valuing Illumina at around $6.60 billion. However, after “careful review and consideration together with its financial and legal advisors”, Illumina’s board have not been persuaded. In
The UK’s National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance recommending Janssen Cilag’s Incivo (telaprevir), in combination with Roche’s peginterferon alfa and ribavirin, as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease. The final draft guidance recommends the drug as an
The U.S. Federal Trade Commission (FTC) has asked Swiss pharmaceutical company, Roche, for more information concerning the $5.7 billion hostile takeover proposal for diagnostics company Illumina Inc. Illumina, which is based in San Diego, makes systems that analyse an individual’s DNA. It is expected that future breakthroughs will use the information to modify treatments in
Drug makers who do not offer any genuine value will “disappear” over the next decade, according to Roche’s chief executive, Severin Schwan. Speaking at the Financial Times’ Pharmaceutical and Biotechnology conference in London, Schwan described a three-segment model with highly-innovative companies on one side and generics on the other. Schwan stated that the number of